Intranasal vaccines for protection against resipratory and systemic bacterial infections

References

• Bogaert D, Hermans PWM, Adrian PV, Rümke HC, deGroot R. Pneumococcal vaccines: an update on current strategies. Vaccine22(17–18), 2209–2220 (2004).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Brandileoni MCC, deAndrade ALSS, Di Fabio JL, Guerra MLLS, Austrian R. Appropriateness of pneumococcal conjugate vaccine in Brazil: towards novel pneumococcal protein vaccines. J. Infect. Dis.187(8), 1206–1212 (2003).
   PubMed Web of Science ®Google Scholar
• Toossi Z, Mayanja-Kizza H, Hirsch CS et al. Impact of tuberculosis (TB) on HIV activity in dually infected patients. Clin. Exp. Immunol.123, 233–238 (2001).
   PubMed Web of Science ®Google Scholar
• Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J.26, 162–167 (2005).
   PubMed Web of Science ®Google Scholar
• Raguckas SE, VandenBusshe HL, Jacobs C, Klepser ME. Pertussis resurgence: diagnosis, treatment, prevention and beyond. Pharmacotherapy27(1), 41–52 (2007).
   PubMed Web of Science ®Google Scholar
• Locht C, Antoine R, Raze D et al. Bordetella pertussis: from functional genome to intranasal vaccination. Int. J. Med. Microbiol.293, 583–588 (2004).
   PubMed Web of Science ®Google Scholar
• Khan FN, Lin M, Hinkle CJ et al. Case–control study of vaccination history in relation to pertussis risk during an outbreak among school students. Pediatr. Infect. Dis. J.25(12), 1132–1136 (2006).
   PubMed Web of Science ®Google Scholar
• Harisson LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev.19(1), 142–164 (2006).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsly C. Mucosal immunity and vaccines. Nat. Med.11(Suppl. 4), 45–53 (2005).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM, Lyke NY, lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75(1), 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15) 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol.13, 293–310 (2003).
   Google Scholar
• Nawar HF, Arce S, Russel MW, Connell TD. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect. Immun.75(2), 621–633 (2007).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol.80(10), 4962–4970 (2006).
   PubMed Web of Science ®Google Scholar
• Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun.72(1), 238–246 (2004).
   PubMed Web of Science ®Google Scholar
• Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect.53(5), 350–356 (2006).
   PubMed Web of Science ®Google Scholar
• Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis85(1–2), 107–114 (2005).
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McSane H, Hannam CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacilli Calmette–Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171(3), 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sasaki K, Takahashi M et al. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus Calmette–Guerin in mice. Vaccine24(17), 3591–3598 (2006).
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping-cough. PLoS Pathog.2(7), 662–670. (2006).
   Web of Science ®Google Scholar
• Berstad AK, Oftung F, Korsvold GE et al. Induction of antigen-specific T cell responses in humans volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine18(22), 2323–2330 (2000).
   PubMed Web of Science ®Google Scholar
• Berstad AK, Holst J, Froholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol.49(2), 157–163 (2000).
   PubMed Web of Science ®Google Scholar
• Alonso S, Willery E, Renaud-Mongerie G, Locht C. Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect. Immun.73(7), 4295–4301 (2005).
   PubMed Web of Science ®Google Scholar
• Malley R, Lipsitch M, Stack A et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun.69(8), 4870–4873 (2001).
   PubMed Web of Science ®Google Scholar
• Malley R, Srivastava A, Thompsom CM et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect. Immun.74(4), 2187–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev.57(9), 1381–1391 (2005).
   PubMed Web of Science ®Google Scholar
• Bermudez-Humarán LG, Langella P, Cortes-Perez NG et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th-1 cytokine production. Infect. Immun.71(4), 1887–1896 (2003).
   PubMed Web of Science ®Google Scholar
• Oliveira MLS, Arêas APM, Campos IB et al. Induction of systemic and mucosal immune response and decrease of Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing the pneumococcal surface antigen A (PsaA). Microbes Infect.8(4), 1016–1024 (2006).
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M, Olson S, Kalina WV et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl Acad. Sci. USA102(8), 2880–2885 (2005).
   PubMed Web of Science ®Google Scholar
• Cangemi de Gutierrez R, Santos V, Nader-Macias ME. Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol. Med. Microbiol.31(3), 187–195 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert C, Robinson K, Le Page RWF, Wells JM. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect. Immun.68(6), 3251–3260 (2000).
   PubMed Web of Science ®Google Scholar
• Oliveira MLS, Monedero V, Miyaji EN, Leite LCC, Ho PL, Perez-Martinez G. Expression of Streptococcus pneumoniae antigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) by Lactobacillus casei. FEMS Microbiol. Lett.227(1), 25–31 (2003).
   PubMed Web of Science ®Google Scholar
• Hannify SB, Carter AT, Hitchin E, Wells JM. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J. Infect. Dis.195, 185–193 (2007).
   PubMed Web of Science ®Google Scholar
• Buccato S, Maione D, Rinaudo CD et al. Use of Lactococccus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J. Infect. Dis.,194, 331–340 (2006).
   PubMed Web of Science ®Google Scholar
• Colombi D, Oliveira MLS, Campos IB, Monedero V, Perez-Martínez G, Ho PL. Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA430–873 fragment expressed in Lactobacillus casei. Curr. Microbiol.53(6), 462–466 (2006).
   PubMed Web of Science ®Google Scholar
• Zegers ND, Kluter E, van Der Stap H et al. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J. Appl. Microbiol.87(2), 309–314 (1999).
   PubMed Web of Science ®Google Scholar
• Lee SF, Halperin SA, Wang H, MacArthur A. Oral colonization and immune responses to Streptococcus gordonii expressing pertussis toxin S1 fragment in mice. FEMS Microbiol. Lett.208(2), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Medaglini D, Ciabattini A, Cuppone AM et al. In vivo activation of naïve CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect. Immun.74(5), 2760–2766 (2006).
   PubMed Web of Science ®Google Scholar
• van Roosmalen ML, Kanninga R, El Khattabi M et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods38(2), 144–149 (2006).
   PubMed Web of Science ®Google Scholar
• Audouy SA, van Roosmalen ML, Neef J et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine24(26), 5434–5441 (2006).
   PubMed Web of Science ®Google Scholar
• Duc le H, Hong HA, Fairweather N, Ricca E, Cutting SM. Bacterial spores as vaccine vehicles. Infect. Immun.71(5), 2810–2818 (2003).
   PubMed Web of Science ®Google Scholar
• Duc le H, Hong HA, Atkins HS et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine25(2), 346–355 (2007).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85-ESTAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guerin immunity. J. Immunol.177(9), 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol. Med. Microbiol.47(2), 233–241 (2006).
   PubMed Web of Science ®Google Scholar
• Hale C, Humphreys IR, Hussell T et al. Mucosal immunization of murine neonates using whole cell and acellular pertussis vaccine. Vaccine22(27–28), 3595–3602, (2004).
   PubMed Web of Science ®Google Scholar
• Lee SF, Halperin SA, Salloum DF, MacMillan A, Morris A. Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimera protein. Infect. Immun.71(4), 2272–2275 (2003).
   PubMed Web of Science ®Google Scholar
• Alonso S, Reveneau N, Pethe K, Locht C. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immnogenicity and protective role. Infect. Immun.70(8), 4142–4147 (2002).
   PubMed Web of Science ®Google Scholar
• Hotomi M, Ikeda Y, Suzumoto M et al. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine23(10), 1294–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Abe N, Kodama S, Hirano T, Eto M, Suzuki M. Nasal vaccination with CpG oligodoexynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope116(3), 407–412 (2006).
   PubMed Web of Science ®Google Scholar
• Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/Usp42 proteins combined with aqueous formulation of RC529. Vaccine22(25–26), 3449–3456 (2004).
   PubMed Web of Science ®Google Scholar
• Briles DE, Ades E, Paton JC et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun.68(2), 796–800 (2000).
   PubMed Web of Science ®Google Scholar
• Balachandram P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles D. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun.70(5), 2526–2534 (2002).
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, Lynch JM, Briles DE, Hollingshead SK, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun.69(11), 6718–6724 (2001).
   PubMed Web of Science ®Google Scholar
• Arêas APM, Oliveira MLS, Miyaji EN et al. Expression and characterization of cholera toxin B–pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB–PsaA to induce humoral immune response in mice. Biochem. Bioph. Res. Comm.321, 192–196 (2004).
   PubMed Web of Science ®Google Scholar
• Pimenta FC, Miyaji EN, Arêas APM et al. Intranasal immunization with the cholera toxin B subunit–pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect. Immun.74(8), 4939–4944 (2006).
   PubMed Web of Science ®Google Scholar
• Park HS, Cleary PP. Active and passive intranasal immunization with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect. Immun.73(12), 7878–7886 (2005).
   PubMed Web of Science ®Google Scholar
• Bowe F, Lavelle EC, McNeela EA et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitides and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun.72(7), 44052–4060 (2004).
   Google Scholar
• Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitides. Vaccine24(26), 5420–5425 (2006).
   PubMed Web of Science ®Google Scholar
• Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol.170(11), 5636–5643 (2003).
   PubMed Web of Science ®Google Scholar
• Sloat BR, Cui Z. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J. Pharm. Pharmacol.58(4), 439–447 (2006).
   PubMed Web of Science ®Google Scholar
• Sloat BR, Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine24(40–41), 6405–6413 (2006).
   PubMed Web of Science ®Google Scholar
• Shoemaker DR, Saunders NB, Brandt BL, Moran EE, Laclair AD, Zollinger WD. Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local and mucosal serum bactericidal antibody responses in rabbits. Infect. Immun.73(8), 5031–5038 (2005).
   PubMed Web of Science ®Google Scholar
• Sabirov A, Metzger DW. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against otitis media. Vaccine24(27–28), 5584–5592 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano T, Jiao X, Chen Z, Van Waes C, Gu XX. Kinectics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol. Lett.107(2), 131–139 (2006).
   PubMed Web of Science ®Google Scholar
• Morón G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol.25(2), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Norman JA, Hobart P, Manthorpe M, Phelgner P, Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine15(8), 801–803 (1997).
   PubMed Web of Science ®Google Scholar
• Oh Y-K, Kim J-P, Hwang TS et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine19(31), 4519–4525 (2001).
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. PNAS98(16), 9318–9323 (2001).
   PubMed Web of Science ®Google Scholar
• Kataoka K, McGhee JR, Kobayashi R, Fujihashi K, Shizukuishi S, Fujihashi K. Nasal Flt3 ligand cDNA elicits CD11c CD8 dendritic cells for enhanced mucosal immunity. J. Immunol.172(6), 3612–3619 (2004).
   PubMed Web of Science ®Google Scholar
• Castagliuolo I, Piccinini R, Beggiao E et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice. Vaccine24(20), 4393–4402 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection against pulmonary tuberculosis. J. Immunol.173(10), 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74(8), 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Miki K, Nagata T, Tanaka T et al. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MBP/MPT51. Infect. Immun.72(4), 2014–2021 (2004).
   PubMed Web of Science ®Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug. Deliv. Rev.57(3), 411–430 (2005).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous hemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine16(20), 2039–2046 (1998).
   PubMed Web of Science ®Google Scholar
• Csaba N, Sánchez A, Alonso MJ. PLGA:Poloxamer and PLGA:Poloxamine blend nanostructures as carriers for nasal gene delivery. J. Control Release113(2), 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun.70(9), 4785–4790 (2002).
   PubMed Web of Science ®Google Scholar
• de Jonge MI, Hamstra HJ, Jiskoot W et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine22(29–30), 4021–4028 (2004).
   PubMed Web of Science ®Google Scholar
• Flick-Smith HC, Eyles JE, Hebdon R et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun.70(4), 2022–2028 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Good CE, Sellner T, Bajaksouzian S, Windau A, Anon JB. Nasopharyngeal carriage of respiratory pathogens in children undergoing pressure equalization tube placement in the era of pneumococcal protein conjugate vaccine use. Laryngoscope117(2), 295–298 (2007).
   PubMed Web of Science ®Google Scholar
• Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int. J. Pediatr. Otorhinolaryngol.71(4), 575–579 (2007).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalation anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis.191(2), 278–288 (2005).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Jones KF et al. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A Streptococcus vaccine. Infect. Immun.73(4), 2360–2366 (2005).
   PubMed Web of Science ®Google Scholar